Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-004150
Filing Date
2023-02-10
Accepted
2023-02-09 17:53:46
Documents
69
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2628467
2 ex31-1.htm EX-31.1 15087
3 ex32-1.htm EX-32.1 6661
  Complete submission text file 0001493152-23-004150.txt   10243225

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20221231.xsd EX-101.SCH 65830
5 XBRL CALCULATION FILE ppcb-20221231_cal.xml EX-101.CAL 65722
6 XBRL DEFINITION FILE ppcb-20221231_def.xml EX-101.DEF 299126
7 XBRL LABEL FILE ppcb-20221231_lab.xml EX-101.LAB 534445
8 XBRL PRESENTATION FILE ppcb-20221231_pre.xml EX-101.PRE 410875
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1590276
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 300662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54878 | Film No.: 23607649
SIC: 2834 Pharmaceutical Preparations